Your browser doesn't support javascript.
loading
The role of E2F2 in cancer progression and its value as a therapeutic target.
Gao, Yang; Qiao, Xinjie; Liu, Zhenhui; Zhang, Wenzhou.
Afiliação
  • Gao Y; Department of Pharmacy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
  • Qiao X; Department of Rhinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Liu Z; Department of Pharmacy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
  • Zhang W; Department of Pharmacy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Front Immunol ; 15: 1397303, 2024.
Article em En | MEDLINE | ID: mdl-38807594
ABSTRACT
The E2F family of transcription factors plays a crucial role in the regulation of cell cycle progression and cell proliferation. Accumulative evidence indicates that aberrant expression or activation of E2F2 is a common phenomenon in malignances. E2F2 has emerged as a key player in the development and progression of various types of tumors. A wealth of research has substantiated that E2F2 could contribute to the enhancement of tumor cell proliferation, angiogenesis, and invasiveness. Moreover, E2F2 exerts its influence on a myriad of cellular processes by engaging with a spectrum of auxiliary factors and downstream targets, including apoptosis and DNA repair. The dysregulation of E2F2 in the context of carcinogenesis may be attributable to a multitude of mechanisms, which encompass modifications in upstream regulatory elements or epigenetic alterations. This review explores the function of E2F2 in cancer progression and both established and emerging therapeutic strategies aiming at targeting this oncogenic pathway, while also providing a strong basis for further research on the biological function and clinical applications of E2F2.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Progressão da Doença / Fator de Transcrição E2F2 / Neoplasias Limite: Animals / Humans Idioma: En Revista: Front Immunol / Front. immunol / Frontiers in immunology Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China País de publicação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Progressão da Doença / Fator de Transcrição E2F2 / Neoplasias Limite: Animals / Humans Idioma: En Revista: Front Immunol / Front. immunol / Frontiers in immunology Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China País de publicação: Suíça